Trial Profile
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms INPULSIS; INPULSIS-2
- Sponsors Boehringer Ingelheim
- 12 Sep 2023 Results of meta analysis to compare FVC findings from the IPF patients enrolled in ATLAS to four studies (ASCEND, NPULSIS-1, INPULSIS-2 and INBUILD) presented in the Avalyn Pharma Media Release.
- 30 Aug 2023 Results of pooled analysis from NCT00514683, NCT01335464, NCT01335477, NCT01979952, NCT02999178, NCT02597933, assessing decline in forced vital capacity (FVC) as a surrogate for mortality, published in the Respirology
- 24 May 2023 Results of post-hoc analyses of INPULSIS 1 and 2 trials has been presented at the 119th International Conference of the American Thoracic Society